Medscape: Antisense Molecule Shows Promise in Duchenne

	A link to the following article was sent to you by: Mohd Tariq Salman Antisense Molecule Shows Promise in Duchenne Muscular Dystrophy Medscape Medical News , 2009-08-26

This message was sent to: mtariqsalman.medicalresearch@blogger.com Medscape attn: Member Support 111 Eighth Avenue New York, NY 10011

USEFUL MEDICAL WEBSITES

mediconet.blogspot.com is a web directory which guides you to find out
websites related with all medical needs, like journals,lectures, e
books,videos,images,references,forums,medical advice...etc.

E BOOKS
PG ENTRANCE
MCQS
VIDEOS
USMLE
REFERENCE
CLINICAL SKILL
SOFTWARES
MEDIA
SUGGEST A SITE

www.medicalppt. blogspot. com  contains more than thousand
Presentations and lecture notes in most fields of medicine.

If you are going to prepare a seminar you can compare with
multiplesimilar presentations given here, some times if you are busy
you canuse these slides as such without any modification or with
slightmodification.

NYTimes.com: Tests Begin on Drugs That May Slow Aging

This page was sent to you by:  mtariqsalman@gmail.com SCIENCE   | August 18, 2009 Tests Begin on Drugs That May Slow Aging By NICHOLAS WADE Excitement among some researchers has picked up with the apparent convergence of lines of inquiry involving genes and restricted diets. Advertisement Amelia stars two-time Academy Award winner Hilary Swank as Amelia Earhart, the legendary aviatrix. Directed by Mira Nai. Click here to view trailer Copyright 2009  The New York Times Company | Privacy Policy

Fwd: US FDA Approves Extavia - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with This Devastating Disease

---------- Forwarded message ----------
From: Drugs.com <sender@list.drugs.com>
Date: 2009/8/18
Subject: US FDA Approves Extavia - the First in a New Portfolio of
Planned MS Therapies from Novartis to Help Patients with This
Devastating Disease
To: mtariqsalman@gmail.com

Sent to you from Drugs.com
New Drug Approval

US FDA Approves Extavia - the First in a New Portfolio of Planned MS
Therapies from Novartis to Help Patients with This Devastating Disease

August 17, 2009

Basel, August 17, 2009 - The US Food and Drug Administration (FDA) has
approved Extavia (interferon beta-1b), the first in a new planned
portfolio of multiple sclerosis (MS) medicines from Novartis to help
patients manage this devastating disease.   Extavia is approved by the
FDA for the treatment of relapsing forms of MS to reduce the frequency
of clinical exacerbations. The therapy is also indicated for patients
who have experienced a first clinical episode of MS...

Read more...

Copyright © 2009 Drugs.com. All rights reserved.

New screening method for Anticancer drugs

Many researchers believe tumour growth is driven by cancerous stem cells that, for reasons not yet understood, are highly resistant to standard treatments. Chemotherapeutic agents may kill off 99 percent of the cells in a tumor, but the stem cells that remain can make the cancer recur or spread to other tissues in the body to cause new cancers.

Stem cells, unlike mature cells, can constantly renew themselves and are thought to be the source of cancers when, through mutations in their DNA, they throw off their natural restraints.
a team at the Broad Institute devised a way of screening for drugs that attack cancer stem cells but leave ordinary cells unharmed.

Cancer stem cells are hard to maintain in sufficient numbers, but the Broad Institute team devised a genetic manipulation to keep breast cancer stem cells trapped in the stem cell state.

The team, led by Piyush B. Gupta, screened some 16,000 chemicals, including all known chemotherapeutic agents approved by the FDA. The team reported in the Cell that 32 of the chemicals selectively went after cancer stem cells. The screening system proves for the first time that it is possible to single out cancer stem cells with drugs that leave ordinary cells alone. Only one of the 32 chemicals is approved as a drug for cancer.

Another approach to concentrating on cancer stem cells, based on the use of antibodies, was reported this month by OncoMed Pharmaceuticals.

The cancer stem cell theory has been thrust into the spotlight in the last five years with the discovery of stem cells in many types of solid tumors, including those of the breast, brain, prostate, colon, bladder and pancreas.

Source: http://www.nytimes.com/2009/08/14/health/research/14cancer.html?_r=1&8au&emc=au

Newer drugs for Epilepsy

Lacosamide

Lacosamide is an amino acid-related compound that has been studied in both pain syndromes and partial seizures.

Mechanism of Action: Lacosamide enhances slow inactivation of voltage-gated Na+ channels. It also binds to the collapsin-response mediator protein, CRMP-2, thereby blocking the effect of neurotrophic factors such as BDNF and NT3 on axonal and dendritic growth.

Rufinamide

Rufinamide is a new triazole derivative with little similarity to other antiseizure drugs. It is approved for use in Lennox-Gastaut syndrome and preliminary evidence suggests that it may also be useful in other difficult-to-treat epilepsy syndromes.

A Guide to the Alternatives to Animal Experimentation

Authors: Dr Syed Ziaur Rahman, MD, Dr Mohd Tariq Salman, MD
Publisher: Ibn Sina Academy of Medieval Medicine and Sciences
1st Edition: 2009, ISBN 978-81-906070-8-7

We teach animal experimentation in all science disciplines. However, since it is now not possible to sacrifice and demonstrate the effects of drugs on animals in large numbers due to ethical considerations; we in medical colleges in India are either shifting or planning to move to alternatives of these experiments. Simulations of many conventional experiments through CAL are now available. "A Guide to the Alternatives to Animal Experimentation” helps students to handle these softwares and see the effects of drugs. This is a remarkable achievement as there is still no such specific guide available in India as far as I know. In the guide, softwares including ExPharm have all been explained very well.While the book by InterNICHE entitled "From guinea pig to computer mouse" is an excellent one meant for faculty and research scientists, this particular guide by Dr Rahman (and myself as co-author) is basically aimed at undergraduate students in pharmacology to help them use the freely available downloadable softwares such as ExPharm, Ep_Dog, Organ Bath Simulation and ReMe independently and learn the effects of drugs. When the students are themselves able handle the softwares (with an instructor nearby to troubleshoot), learning becomes so easy and interesting.

To get a copy please contact me.

'Good Clinical Practices' HelpDesk

The GCP HelpDesk is a support service provided to respond to queries raised by Investigators/Physicians on Good Clinical Practice in Clinical Research. It provides a central point of contact on global GCP issues and ensures that consistent replies are provided to questions. The HelpDesk also allows the users to give their feedback, which will be continuously reviewed in order to improve its services and helps in regularly updating the list of Frequently Asked Questions (FAQs) published on its website. In this website you will find Good Clinical Practice (GCP) related information for the Clinical Research Industry professionals on request.

The GCP HelpDesk is designed to provide information for clinical research professionals with questions regarding handling, conducting and managing clinical research as per GCP, FDA and other Regulations. This HelpDesk is aimed to provide transparency from resources and expertise in the field of Clinical Research with the recent developments and changes in the guidelines for clinical research professionals.The GCP HelpDesk is a searchable website that will match the question with solution by industry experts and other dedicated sites to a specific area. Both simple and complicated questions are welcomed.

To create an account and start using the services go to: http://www.gcphelpdesk.com/index.php/component/user/?task=register